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W. Mlekusch,* M. Schillinger and E. MinarDivision of Internal Medicine II, Department of Angiology, Medical University of Vienna,
Waehringer Gu¨rtel 18-90, 1090 Vienna, AustriaErgotism is a rare clinical condition caused by ergot-alkaloid intoxication or pharmacodynamic interactions. The
pathophysiology is based on arterial spasm in different segments of the arterial tree. Ergot-alkaloids are frequently prescribed
as treatment for severe migraine. Ergotamine overdose is often based on interactions with other drugs using the same
metabolic pathway. We report a case of a 28 year old HIV positive male patient on protease-inhibitors, who developed
ergotism under the co-treatment of migraine by ergot-alkaloids.Keywords: Ergotism; Protease-inhibitors; HIV-infection; Critical limb ischemia; Drug interaction.Introduction
The accidental ingestation of Claviceps purpurea
caused widespread epidemics of myocardial infarc-
tion or critical limb ischemia in the middle ages.1 The
initial symptoms of such an intoxication with ergota-
mines are rather mild and very similar to those of a
simple gastrointestinal disorder. Ergotamines exert
directly vasoconstrictive and centralsympatholytic
effects.2 The vasoconstrictive properties are mainly
based on agonistic impact on 5-HT1B/1D- and 5-HT2-
receptors. Furthermore, ergotamines have peripheral-
noradreneric blocking capabilities.3 Therefore, ergota-
mines are frequently prescribed due to severe and life-
style limiting migraine. Nowadays, pure nutrient-
based intoxications are rare, in contrast intoxications
based on pharmacodynamic interactions are fre-
quently observed and reported in the literature.4–15
We report a case of a 28 years old HIV-positive male
patient, who is under protease inhibiting therapy. He
was referred to our institution due to critical limb
ischemia. He has recently been started on ergot-ing author. Dr Wolfgang Mlekusch, Division of
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was no obvious connection between his current
medication and the objective presence of critical limb
ischemia.Case Report
We report the case of a 28 year old male patient,
referred from the department of emergency medicine
to our in-patient-ward. The patient reported paraes-
thetic pain in both legs, which had developed over the
past 2 weeks. The reported level pain was increasing
continuously. There was no history of claudication and
no comparable episode in the patients’ history. The
patient was HIV positive and an infection with
hepatitis-C-virus was also known. He had a history
of intravenous drug-abuse, currently prescribed
methadone-substitution. The patient had been started
on ergotamine therapy according to severe migraine 1
week before the onset of his leg complaints. In detail,
the patients medication was doxepin 125 mg daily,
carbamazepin 900 mg daily, nelfinavir 200 daily,
stadivudin 80 mg daily, lamivudine 5600 mg
daily, oxacepam 90 mg daily, methadone 140 mgEJVES Extra 9, 25–28 (2005)
doi:10.1016/j.ejvsextra.2005.01.007, available online at http://www.sciencedirect.com onD license.
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therapy with clopidogrel 75 mg daily was started.
Physical examination revealed pale and cool limbs.
Sensory and motor functions were partly impaired.
Only the groin pulse was palpable in both legs. At the
time of admission there was no detectable changes in
the peripheral pulse volume recordings. The systolic
pressure was reduced to 40 mmHg on both Aa. tibiales
anteriores. The Aa. dorsalis pedis were undetectable
with hand held Doppler. The Ankle-brachial-index
was 0.35 right and left, respectively. The electrocardio-
gram and the echocardiogram showed no signs of
arrhythmia or thrombus formation. At admission,
duplex-ultrasound scan revealed extraordinary thin
superficial femoral and popliteal arteries. The calf-
arteries were not visible with duplex ultrasound.
Several laboratory analysis have been performed.
The aminotransferases were slightly increased (ALTFig. 1. i.a.DSA before parenteral treatment with
nitroglycerine.
EJVES Extra Vol 9, March 200571 U/l, AST 27 U/l). In contrast, the serum albumin
level (41.6 g/l), cholinesterase level (6.1 kU/l) and the
prothrombin time (100%) were within normal ranges.
Creatinin kinase (198 U/l), myoglobin (356 mg/ml)
and lactate-dehydrogenase (450 U/l) levels were
elevated. To provide limb salvage an intra-arterial
digital subtraction angiogram was performed. Similar
to the ultrasound scan, the superficial femoral and the
popliteal arteries were of extraordinary thin diameter
and the calf-arteries were also not visible. Thrombus
formations or relevant stenotic lesions have not been
found during angiography. Due to the ‘negative’
angiogram and the pharmacotherapeutic record the
suspicion of ergotamine overdose raised. According to
this assumption the patient received immediately an
high-dose vasodilative therapy (nitroglycerine and
Alprostadil) for the following days. The signs of
critical limb resolved within the first 24 h of treatment
(Figs. 1–3). Duplex ultrasound the day after initialized
vasoactive therapy showed a remarkable improve-
ment. The diameter of the superficial femoral and
popliteal arteries was increased compared to the initial
scan. In the physical examination, all pulses of the legs
were palpable. Even the pulse volume recordings
returned to normal levels and the ankle-brachial index
was O1.0 on both sides. Six days after the first
angiography the patient underwent another angio-
gram to confirm this treatment success. After 8 days of
in-ward treatment, the patient was dismissed in
excellent clinical condition. A follow-up examination
after 8 months revealed again no hemodynamic
impairment documented by pulse volume recordings
and measurement of the ankle-brachial-index.Discussion
Based on recently started anti-migraine therapy con-
taining ergotamines ergotism had been suspected and
this diagnosis had been supported by ruling out other
causes of critical limb ischemia. It is known from the
literature, that similar therapeutic regimen can cause
ergotamine overdose by interaction with protease-
inhibitor therapy5–8,11–15 or other treatment.16 True
ergotism is rare, however, of remarkably clinical
importance in patients with extensive anti-viral
therapy. Since the start of protease-inhibitors in
medical therapy in 1994 several similar cases have
been reported. The majority of patients were male and
younger than 40 years of age.5–8,11–15
It can be speculated that HIV infection itself has any
impact on the development of ergotamine overdose.
Additionally, an impaired liver metabolism exhibit
such amplifying properties by inhibition of the
Fig. 2. i.a.DSA after parenteral treatment with nitroglycerine.
Fig. 3. Oszillogram at admission, nach after parenteral
treatment and 8 months after discharge.
Ergotism and HIV Infection 27cytochrome P450 pathway.17 In fact our patient
showed slightly elevated aminotransferases, but the
serological markers of liver metabolism were within
normal ranges. It is very important to do laboratory
analysis frequently to rule out possible complications
like acute renal failure based on crush syndrome,
acidosis or shock.18 Additionally, it seems reasonable
to monitor the patients ECG continuously, to detect
possible arrhythmias in time. Pharmacotherapeutics,
which are frequently used, are crystalloid infusion,
mannitol and bicarbonate. Especially, last one is
advocated as helpful in minimizing renal damage
after rhabdomyolsis.18 We had to distinguish between
vasospasm and atherosclerosis. The golden standard
in the diagnosis of peripheral artery disease is the
intra-arterial angiography. In cases of ergotamine
overdose-related vasospasm, the vessel wall is
smooth. In our case a simple morphologicaldetermination was difficult because of the extensive
vasospasm. Therefore, the diagnosis was confirmed by
the angiographic missing of any luminal narrowing
and the positive effect of the vasoactive therapy.
Therapeutic options are immediately treatment
stop for the presumed cause. Peripheral vasoactive
substances can be safely administered, either orally or
intravenously. Nitroglycerine-derivates, calcium-
channel-antagonists, alpha-blocking-agents and pros-
tanoids are possible first-choice therapy. An additional
heparin therapy seems reasonable, too. Nowadays,
ergotamine overdose-related vasospasm and resulting
critical limb ischemia is rare. However, due to
extensive use of ergotamines in the treatment of
migraine such kind of secondary vasospasm is a
considerable differential diagnosis and should be kept
in mind. Furthermore, migraine-therapy containing
ergotamines should be administered only under
certain precaution and close follow-up visits.EJVES Extra Vol 9, March 2005
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